¿¼²©±¨°à ¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ÿÈÕÇ©µ½
Ö÷Ìâ : µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£©

µÚËÄÒ½¿Æ´óѧ1998ÄêÃâÒßѧ£¨×¨»ù£©£¨²©Ê¿£© d "25e"(~F  
w d6+,B  
  Ò»¡¢Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© NUh+ &M  
  1¡¢Co-stimulators (or co-stimulating molecules) ^*b11 /7  
  2¡¢NK-kB |%uy{  
  3¡¢Immunoglobulin superfamily wQYW5X  
  4¡¢antigen-presenting cell (APC) -'T^gEd) c  
  5¡¢death domain |xrnLdng0R  
  6¡¢CCR and CXCR |y4j:`@.  
  7¡¢Lectin (or mitogen) ,8o Y(h  
  8¡¢Clusters of differentiation, CD) 5% w08  
  9¡¢B7 family d 9]zB-A  
  10¡¢Cytotoxic T lymphocyte, CTL) B#4'3Y-3  
  11¡¢IL-15 and IL-15 receptor (IL-15R) .9q`Tf  
  12¡¢MHC restriction VBz G`&NG  
  13¡¢Affinity-chromatography V`}u:t7r  
  14¡¢Cyctosprin A, CsA n&8SB'-r  
  15¡¢Antibody-dependent cell-mediated cytotoxicity, ADCC) W!JEl|]  
9>= S@hVMd  
  ¶þ¡¢¼ò´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© ^G NL:D%6d  
  1¡¢ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 n$<n Yr`X  
  2¡¢ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØϵ¡£ _% i!LyG  
  3¡¢ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌص㡣 ut.tf \c  
~R~eQ=8  
  Èý¡¢ÎÊ´ðÌ⣨25·Ö£© $`<-;kI  
  1¡¢Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ { }P~nP  
  ѪҺ²¡Ñ§×¨Òµ£º 5 Q,j+  
  2¡¢ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎΪÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
Ãâ·Ñ¿¼²©ÂÛ̳ÍøÖ·ÊÇʲô? ÕýÈ·´ð°¸:freekaobo.com
°´"Ctrl+Enter"Ö±½ÓÌá½»